作者: Naoto T. Ueno , Judith K. Wolf , David M. Gershenson , Gabriel N. Hortobagyi , Mien-Chie Hung
DOI: 10.1007/978-1-59745-222-9_21
关键词:
摘要: At The University of Texas M.D. Anderson Cancer Center, we have been investigating use the adenovirus type 5 ElA gene as a cancer therapy for breast or ovarian since 1995. is nonimmunologic approach involving ectopic expression potentially therapeutic in cells. During late 1980s, E1A was shown to downregulate overexpression HER-2/neu, thus reversing tumorigenic and metastatic phenotype HER-2/neu-overexpressing Since that time, has also function tumor suppressor several other types cells by inducing apoptosis differentiation inhibiting metastasis regardless HER2 level. This chapter highlights some issues difficulties encountered designing clinical trials cancer.